Rwanda experienced the first outbreak of Marburg virus, which was declared on 27 September 2024 and ended on 20 December 2024 after 42 days with no new cases.[3][2] A total of 66 cases were reported, of which 15 were fatal, representing a case fatality rate of approximately 23%.[3][2] Most of those infected were health workers in two hospitals in Kigali who cared for patients.[3][2] The rapid response included massive contact tracing, testing, and the introduction of a phase II clinical trial of the vaccine by the Sabin Vaccine Institute just 10 days after the outbreak was declared.[1][2] Rwanda has also launched the world's first clinical trials of Marburg drugs in collaboration with the WHO.[3] This success was achieved through robust preparedness, partnerships and a strong health system.[1][3] Research with up to 300 participants, including those cured, examines immunity after overcoming the disease.[2]